Press release from Companies
Published: 2024-11-21 07:55:00
Copenhagen, Denmark, 21 November 2024 - Today is the first day for the exercise of Curasight A/S’ ("Curasight" or "the Company" - TICKER: CURAS) warrants of series TO2 (“TO2”), which were issued in connection with the Company's preferential rights issue and directed issue of units in September 2024. The exercise period will run until December 5, 2024. Holders of TO2 are entitled to subscribe for one (1) new share in Curasight for each TO2 at an exercise price of DKK 11.50 per share. If all warrants of series TO2 are exercised, Curasight can receive a maximum of approximately DKK 42.4 million before the deduction of issue costs. An information document is available on the respective websites of Curasight (www.curasight.com) and Sedermera Corporate Finance AB (www.sedermera.se).
In September 2024, Curasight carried out both a rights issue and directed issue of units. Through the rights issue and directed issue, 3,683,814 warrants of series TO2 were issued. Each TO2 entitles the holder to subscribe for one (1) new share in Curasight during the exercise period, which runs from and including 21 November 2024 until and including 5 December 2024. The exercise price for TO2 has been set at DKK 11.50 per share. In the event of full utilization of warrants of series TO2, approximately DKK 42.4 million will be added to the Company before issue costs.
Upon full utilization of TO2, the number of shares in Curasight will increase by 3,683,814 shares to a total of 24,366,241 shares and the share capital will increase by DKK 184,190.70 to DKK 1,218,312.05. The dilution at full utilization amounts to approximately 15.1 percent of the capital and votes.
Complete terms and instructions for warrants of series TO2 are available on the Company's website (www.curasight.com). An information sheet containing summary information about the warrant exercise will be available on Curasight’s, Sedermera Corporate Finance AB's (www.sedermera.se).
Important dates
Warrants of series TO3
Warrants of series TO3 will have an exercise period that runs from and including 4 June 2025 until and including 18 June 2025. The exercise price for the TO3 Warrants will be set to 70 percent of the volume-weighted average price during the period of twenty (20) trading days ending two (2) trading days before the first day of the exercise period, with a discount of 30 percent and be within the range DKK 15.55-19.40. Through the exercise of warrants of series TO3, Curasight can receive a maximum of approximately DKK 35.7 million. The warrants of series TO3 are subject to trading at Spotlight Stock Market.
Advisors
Sedermera Corporate Finance AB is the Company's financial advisor in connection with the capitalization. DLA Piper is the Company's legal advisor and Danske Bank is the settlement agent.
For more information regarding Curasight, please contact:
Ulrich Krasilnikoff, CEO
Phone: +45 22 83 01 60
E-mail: uk@curasight.com
www.curasight.com
For more information regarding the warrants, please contact:
Sedermera Corporate Finance AB
Phone: +46 40 615 14 10
E-mail: cf@sedermera.se
www.sedermera.se
Curasight is a clinical development company based in Copenhagen, Denmark. The Company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging (uTRACE®) and Radioligand Therapy (uTREAT®) Theranostic Platform targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology is expected to improve diagnosis and provide more gentle and efficient treatment of multiple cancer types.
